AceCosm’s website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers, FDA says.
What happened
FDA reviewed www.acecosm.com and found it offering injectable botulinum toxin type A products, including [SET] NABOTA 200U + SALINE 20ML and Nabota 200U Botulinum Toxin Type A, for sale to U.S. consumers. FDA said the site’s claims show the products are drugs intended for human use, such as prevention of chronic migraine and treatment of urinary incontinence. FDA said there are no approved applications for these products and their labeling lacks adequate directions for use.
What FDA found
FDA says the website offers injectable botulinum toxin drugs that are unapproved new drugs because no FDA-approved application is in effect for them.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]FDA says the labeling lacks adequate directions for use, making these prescription drugs misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]FDA says offering these drugs for sale causes misbranded drugs to be introduced into interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells AceCosm to stop offering any unapproved and misbranded drugs to U.S. consumers and to respond in writing within 15 working days with specific corrective steps and related documentation.
Who should pay attention
- U.S. consumers who buy injectables online
- clinics or med spas considering imported botulinum toxin
- online sellers of prescription injectable drugs
This is a summary. Read the original letter on fda.gov.